Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck Outlines Plans For 2009 NDA Filings; Migraine Drug Is Best Bet

Dec 22 2008

• By Wendy Diller

Related Content

Merck’s Ambitious Plans For Follow-On Biologics

Dec 15 2008

As Sales Slip, Merck &amp; Co. Plans 7,200 Job Cuts

Oct 22 2008

Taranabant Loss No Surprise For Obesity Field, But Shock To Merck’s Pipeline

Oct 06 2008

Merck Revises Guidance To Include $700 Million Less In Vytorin/Zetia Sales

Apr 21 2008

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window